Tivic Health Systems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 15, 2022 at 03:17 pm EDT
Share
Tivic Health Systems, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 0.528 million compared to USD 0.268 million a year ago. Net loss was USD 3.02 million compared to USD 1.09 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.46 a year ago.
For the six months, sales was USD 0.956 million compared to USD 0.591 million a year ago. Net loss was USD 5.26 million compared to USD 2.45 million a year ago. Basic loss per share from continuing operations was USD 0.55 compared to USD 1.04 a year ago.
Tivic Health Systems, Inc. is a commercial-stage health tech company advancing the field of bioelectronic medicine. The Companyâs patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Its non-invasive and targeted approach to the treatment of inflammatory chronic health conditions is intended to give consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. The Companyâs first commercial product, ClearUP, is an FDA approved handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and available through online retailers and commercial distributors. ClearUP is sold in the U.S. directly to consumers on various platforms and through reseller channels. The Company is also focused on its intellectual property (IP) portfolio and research programs related to vagus nerve stimulation to expand its applications in non-invasive bioelectronic medicine.
TIVIC HEALTH SYSTEMS, INC. 
